Navigating a breast cancer diagnosis: Why tailored treatment protocols hold the key to recovery

Breast cancer remains one of the most pressing global health challenges, transcending geographic and social boundaries. With statistics suggesting that one in eight women may develop the disease during their lifetime, raising awareness about prevention and advanced treatment is more critical than ever. Dr Sanju Cyriac, Head of the Oncology Department at Rajagiri Hospital in Kochi, explains how to navigate a breast cancer diagnosis and how it is treated.

Combating the cancer
Combating breast cancer requires a dual approach: adopting lifestyle modifications to lower overall risk, and establishing rigorous screening habits—such as regular mammograms and breast self-examinations—to facilitate early detection. Today, a breast cancer diagnosis is no longer a condition to be feared. Decades of clinical research have paved the way for highly structured, protocol-driven therapies that deliver remarkably successful recovery rates.

A patient's journey
To understand how modern breast cancer care works, it helps to look at a typical patient journey. Consider Leela, a 49-year-old mother of two college-going sons, whose husband is a farmer. One day, she noticed a distinct, painless lump in her left breast. After discussing it with her family, she visited a doctor who advised an immediate mammogram. Based on the imaging results, the clinical team recommended a needle biopsy, which ultimately confirmed she had breast cancer. Leela's experience is shared by nearly 90 per cent of patients, who usually discover the disease after noticing a physical change or undergoing routine screenings. From this point on, systematic diagnostic tools dictate the precise roadmap for her recovery.

Staging and typing: The building blocks of cancer care
Once a biopsy confirms the diagnosis, the patient is referred to an oncologist. Before any treatment can begin, the medical team must establish two crucial factors: the stage of the cancer and its biological type. Staging determines how far the cancer has spread within the body. While a comprehensive PET scan is the standard diagnostic choice, early-stage cancers can often be evaluated using targeted CT and ultrasound scans. Typing, on the other hand, identifies the cellular behaviour of the tumour using an immunohistochemistry (IHC) test on the biopsy sample. This test classifies breast cancer into three primary categories: hormone-receptor-positive, HER2-positive, or triple-negative. This dual-assessment protocol ensures that patients receive the most effective targeted therapy.

Navigating stages and tailored treatment protocols
Cancer staging ranges from one to four, with stages one to three classified as early or locally advanced. For these stages, the primary goal of the medical team is a complete cure. In stage four, where the cancer has spread to distant organs, the focus of therapy shifts to long-term management, slowing progression, and maintaining quality of life. Treatment pathways are meticulously designed around the molecular type of the tumour. For example, stage one patients generally proceed directly to surgery. In stage two, if the cancer is HER2-positive or triple-negative, oncologists typically prescribe neo-adjuvant therapy—administering chemotherapy or targeted immunotherapy before surgery to shrink the tumour. Conversely, hormone-positive stage two patients are usually advised to undergo surgery first.

The role of neo-adjuvant therapy and advanced surgery
For stage three breast cancers, neo-adjuvant chemotherapy is the standard initial step regardless of the biological type, though the drug combinations will vary. In Leela's case, she was diagnosed with stage two HER2-positive breast cancer. Her oncologist recommended a combination of chemotherapy and targeted anti-HER2 immunotherapy. Crucially, modern surgical oncology prioritises breast-conserving surgery over complete mastectomy whenever clinically safe. This preservation of breast tissue provides immense physical and emotional reassurance to patients, dismantling the outdated belief that the entire breast must always be removed to ensure safety.

Clinical precision with tumour clip placement
When patients undergo neo-adjuvant chemotherapy, tumours often shrink so dramatically that they can become undetectable on scans. To prevent the surgical team from losing track of the exact tumour site during surgery, a tiny, harmless metallic clip is placed inside the tumour before chemotherapy begins. This clip serves as a precise guide during the subsequent operation. Leela underwent this procedure, receiving six cycles of chemotherapy alongside targeted immunotherapy. Following her successful treatment, surgery was performed, and the tissue was sent to pathology. The results showed a "complete pathological response," meaning no active cancer cells remained. This optimal outcome is achieved in 50 to 60 per cent of patients today, reducing the long-term recurrence rate to under 10 per cent.

A collaborative, multidisciplinary approach to recovery
Even if residual cancer cells are found after surgery, clinical teams can adjust post-surgical treatments with alternative targeted medications to ensure excellent long-term survival rates. Leela has now completed her treatment and returned to her daily life, healthy and active. Because modern breast cancer therapy is highly complex, it should never be managed by a single specialist. A successful outcome relies on a multidisciplinary tumour board comprising surgical, medical, and radiation oncologists, alongside pathologists and radiologists. Patients are strongly advised not to rush into treatment decisions without thorough evaluation, as hurried steps can lead to suboptimal clinical paths. Structured, scientific care is a patient's absolute right, and delivering it is the standard of modern medicine.